NEOG
Neogen Corporation
Healthcare · Medical - Diagnostics & Research
Undervalued·Quality 75·RSI 49·DCF -310%·Conviction 80
Investment Thesis — Neogen Corporation
The market underestimates Neogen's ability to leverage its recent M&A integrations to drive operational synergies and margin expansion, focusing too narrowly on its current high multiple and ignoring the inflection in earnings power. Investors are mispricing the durability of Neogen's recurring revenue streams in food safety and animal health, which are less cyclical than the market assumes.
Catalysts
- Earnings beats driven by synergy realization and margin expansion
- New regulatory mandates increasing demand for food safety testing
- Successful cross-selling of animal health and food safety products
Risk Factors
- Integration missteps or delays in realizing synergies
- Regulatory changes reducing demand for core products
- Increased competition compressing margins in key segments
Key Debates
Revenue growth inflects positive by Q4, re-rating P/E.
32.94x Fwd P/E compresses by H2 without growth.
Overbought RSI triggers correction to 11.00 PT by Q3.